In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer
The obtained results pave the way for the use of the newly defined ICI molecules <i>Ngp</i>, <i>Hba-a1</i>, and <i>S100a8</i> as novel immunotherapeutic targets in further preclinical and clinical studies in HCC patients.
Authors
- Michael P. Manns (ORCID: https://orcid.org/0000-0002-4485-8856)
- Ralf Lichtinghagen (ORCID: https://orcid.org/0000-0003-4659-9453)
- Huizhen Suo
- Juan Carlos López Alfonso (ORCID: https://orcid.org/0000-0003-2432-5953)
- Ruibing Shi
- Frank Klawonn (ORCID: https://orcid.org/0000-0001-9613-182X)
- Andreas Jeron
- Lothar Groebe
- Lisa Hoenicke (ORCID: https://orcid.org/0000-0003-0613-8337)
- Dunja Bruder
- Robert Geffers (ORCID: https://orcid.org/0000-0003-4409-016X)
- Michael Jarek (ORCID: https://orcid.org/0000-0001-7751-9458)
- Henrike Lenzen (ORCID: https://orcid.org/0000-0002-0903-1415)
- Nils Jedicke
- Inga Hochnadel
- Nataliia Petriv (ORCID: https://orcid.org/0000-0002-3816-1390)
- Tatjana Hirsch
- Kai Timrott (ORCID: https://orcid.org/0000-0003-1192-3102)
- Tetyana Yevsa (ORCID: https://orcid.org/0000-0003-0377-9198)
- Н. С. Бондаренко
- Chantal Olijnik
Institutions
- Ostfalia University of Applied Sciences (DE)
- Medizinische Hochschule Hannover (DE)
- Helmholtz Centre for Infection Research (DE)
- Deutsches Herzzentrum München (DE)
- Technical University of Munich (DE)
- Technische Universität Braunschweig (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1549229
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.00